Jiajia Zhou
Research Investigator
Surgery
[email protected]

Available to mentor
Jiajia Zhou
Research Investigator
  • Qualifications
  • Research Overview
  • Links
  • Recent Publications
    • Qualifications
    • Research Fellow
      University of Michigan Medical School, Ann Arbor
    • PHD
      University of Science and Technology of China, Hefei
    Research Overview

    I am interested in cancer immunotherapy. Immunotherapy has proven to be an effective treatment for cancer patients, with the primary objective of generating durable protective immunity mediated by effector T cells, leading to the eradication of tumors in patients. Despite the promise of this approach in restoring and enhancing immune cell function, one major limitation is that the majority of tumor microenvironment forms a barrier against effective T cells, thus hampering T cell trafficking and functionality, and current immunotherapeutic strategies. A better understanding of immune barrier and signaling mechanism in effector T cells is essential for our efforts to prevent and treat cancer. We are currently focused on studying how tumors and their microenvironment influence T cell trafficking and function, as well as how scientific advances may help overcome these hurdles. We hope that our research will provide theoretical basis and clues for the treatment of cancer patients in the United States.

    Links
    • https://scholar.google.com/citations?hl=en&user=THX__RkAAAAJ&view_op=list_works&sortby=pubdate
    Recent Publications See All Publications
    • Journal Article
      Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance.
      Yu J, Yan Y, Li S, Xu Y, Parolia A, Rizvi S, Wang W, Zhai Y, Xiao R, Li X, Liao P, Zhou J, Okla K, Lin H, Lin X, Grove S, Wei S, Vatan L, Hu J, Szumilo J, Kotarski J, Freeman ZT, Skala S, Wicha M, Cho KR, Chinnaiyan AM, Schon S, Wen F, Kryczek I, Wang S, Chen L, Zou W. Cell, 2024 Aug 22; 187 (17): 4713 - 4732.e19. DOI:10.1016/j.cell.2024.06.012
      PMID: 38968937
    • Journal Article
      The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
      Zhou J, Kryczek I, Li S, Li X, Aguilar A, Wei S, Grove S, Vatan L, Yu J, Yan Y, Liao P, Lin H, Li J, Li G, Du W, Wang W, Lang X, Wang W, Wang S, Zou W. Nat Immunol, 2021 Apr; 22 (4): 460 - 470. DOI:10.1038/s41590-021-00888-3
      PMID: 33767425
    • Journal Article
      CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy.
      Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. Nature, 2019 May; 569 (7755): 270 - 274. DOI:10.1038/s41586-019-1170-y
      PMID: 31043744